![Assay: Irreversible inhibition of rat brain cytosolic MAGL assessed as [3H] - EMBL-EBI](https://cedclinic.com/wp-content/uploads/2026/06/ced-pexels-4226264-1-150x150.jpg "Assay: Irreversible inhibition of rat brain cytosolic MAGL assessed as [3H] - EMBL-EBI 1")
Scientist explains ‘only two methods’ to stop weed smoker’s horrific ‘scromiting’ side effect
#76 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Cannabinoid Hyperemesis Syndrome (CHS) represents a serious adverse effect that clinicians must recognize and counsel patients about, as it involves uncontrollable vomiting that can lead to dehydration, electrolyte imbalances, and hospitalizations. Understanding the two evidence-based management approaches—cessation of cannabis use and symptomatic treatment with capsaicin topicals—enables clinicians to provide informed guidance to patients experiencing this condition and to differentiate it from other causes of chronic vomiting. Patients using cannabis chronically should be screened for CHS symptoms during intake assessments so that clinicians can intervene early and prevent progression to severe disease.
Cannabinoid hyperemesis syndrome (CHS) is a paradoxical condition affecting frequent cannabis users characterized by severe cyclic vomiting episodes colloquially termed “scromiting.” The syndrome is believed to arise from dysregulation of the endocannabinoid system, which normally maintains homeostasis across multiple physiologic systems, though the exact mechanistic pathway remains incompletely understood. Current evidence supports only two effective management approaches: complete cannabis cessation and capsaicin cream applied topically to the abdomen, with the latter providing symptomatic relief in some patients. Clinicians should maintain a high index of suspicion for CHS in patients presenting with intractable nausea and vomiting who report chronic cannabis use, as this condition is increasingly recognized and frequently misdiagnosed. The syndrome highlights an important therapeutic paradox where cannabis compounds can trigger rather than alleviate certain gastrointestinal symptoms in susceptible individuals. Clinicians should counsel patients about CHS risk and counsel heavy cannabis users to recognize early warning signs, as prompt cessation offers the most reliable path to symptom resolution.
“Cannabinoid Hyperemesis Syndrome is real and serious, but it’s almost entirely preventable through dose management and product transparency, yet we keep seeing patients suffer because they’re using high-potency isolates without understanding their cumulative effects on the endocannabinoid system.”
? Cannabinoid hyperemesis syndrome (CHS) remains a poorly understood adverse effect among regular, high-potency cannabis users, and the proposed mechanism involving dysregulation of the endocannabinoid system offers a partial explanation for this paradoxical symptom cluster of severe nausea and vomiting. While the article’s emphasis on cessation and capsaicin as treatment options aligns with existing clinical evidence, the claim that cannabis compounds are “very safe” oversimplifies a growing body of literature documenting dose-dependent and individual susceptibility factors in adverse outcomes, particularly with increasingly potent tetrahydrocannabinol products now available. Clinicians should recognize that patients presenting with refractory nausea and vomiting, especially those with compulsive hot bathing behavior or abdominal pain, may have CHS rather than other common etiologies, and a detailed substance use history focusing on
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
